RadNet has acquired ultrasound AI vendor See-Mode Technologies, aiming to enhance workflow efficiency and expand its imaging AI offerings.
Key Details
- 1RadNet completed the acquisition of See-Mode Technologies, an AI company focused on breast and thyroid ultrasound analysis.
- 2See-Mode's FDA-cleared thyroid solution is already deployed at some RadNet outpatient centers, showing a 30% reduction in scan times.
- 3Approximately 20 million ultrasound exams for thyroid and breast are performed annually in the US, highlighting a large addressable market.
- 4RadNet plans to integrate See-Mode’s products into its DeepHealth AI portfolio and market them to third parties.
- 5The deal follows earlier acquisitions of iCAD, Quantib, Aidence, and Kheiron by RadNet, further bolstering their AI division.
- 6Financial terms of the acquisition were not disclosed.
Why It Matters
This acquisition demonstrates RadNet's commitment to expanding AI-driven workflow improvements in high-volume, complex ultrasound exams, potentially increasing access and efficiency. The integration of advanced AI solutions is positioned to benefit both clinicians and patients, with commercial implications for the broader radiology AI market.
Source
Radiology Business
Related News
•Radiology Business
RadNet and Desert Oasis Launch No-Cost AI Breast Cancer Screening
RadNet partners with Desert Oasis Healthcare to provide AI-enhanced breast cancer detection at no extra cost.
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•AI in Healthcare
FDA Seeks Real-World Performance Insights on AI Medical Devices
FDA calls for healthcare worker feedback to enhance monitoring of AI-enabled medical devices in real-world settings.